

FOI 1659

14/06/2023

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Q1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Apremilast
- Bimekizumab
- Brodalumab
- Certolizumab
- Deucravacitinib
- Dimethyl fumarate
- Etanercept - Enbrel
- Etanercept Biosimilar
- Guselkumab

Answer 1:

• Adalimumab - Humira	33
• Adalimumab Biosimilar	226
• Apremilast	Information not held
• Bimekizumab	0
• Brodalumab	9
• Certolizumab	<5
• Deucravacitinib	0
• Dimethyl fumarate	Information not held
• Etanercept - Enbrel	<5
• Etanercept Biosimilar	<5
• Guselkumab	58

The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

Part 2:

- Infliximab - Remicade
- Infliximab Biosimilar
- Ixekizumab
- Risankizumab
- Secukinumab
- Tildrakizumab
- Ustekinumab

Answer to part 2:

• Infliximab - Remicade	0
• Infliximab Biosimilar	7
• Ixekizumab	89
• Risankizumab	49
• Secukinumab	27
• Tildrakizumab	8
• Ustekinumab	29

Q2. How many patients were treated in the last 3 months by the Dermatology department for Hidradenitis Suppurativa (HS) ONLY with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Infliximab - Remicade
- Infliximab Biosimilar
- Secukinumab
- Ustekinumab

Answer 2:

• Adalimumab - Humira	22
• Adalimumab Biosimilar	36
• Infliximab - Remicade	0
• Infliximab Biosimilar	<5
• Secukinumab	<5
• Ustekinumab	0

The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the



Southern Health and Social Care Trust

information requested. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

Part 3:

Q3. How many patients were treated in the last 3 months by the Dermatology department for Psoriasis ONLY in the last three months with the following:

- Ciclosporin -
- Methotrexate - any form and strength
- Methotrexate injections 15mg and above

Answer to Question 3:

- | | |
|--|----------------------|
| • Ciclosporin - | 19 |
| • Methotrexate - any form and strength - | 114 |
| • Methotrexate injections 15mg and above – | Information not held |

Email: Foi.Team@Southerntrust.hscni.net